BMGL PE Ratio & Valuation,Is BMGL Overvalued — Intellectia
BMGL Relative Valuation
BMGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BMGL is overvalued; if below, it's undervalued.
Historical Valuation
Basel Medical Group Ltd(BMGL) is now in theFairzone, suggesting that its currentforward PSratio of0.00is consideredFairlycompared with the five-year average of0.00.The fair price ofBasel Medical Group Ltd(BMGL)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.76
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Basel Medical Group Ltd. (BMGL) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Basel Medical Group Ltd. (BMGL) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Basel Medical Group Ltd. (BMGL) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Basel Medical Group Ltd. (BMGL) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Basel Medical Group Ltd. (BMGL) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Basel Medical Group Ltd (BMGL) has a current Price-to-Book (P/B) ratio of 4.24. Compared to its 3-year average P/B ratio of 8.10 , the current P/B ratio is approximately -47.70% higher. Relative to its 5-year average P/B ratio of 8.10, the current P/B ratio is about -47.70% higher. Basel Medical Group Ltd (BMGL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -11.91%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -11.91% , the current FCF yield is about -100.00% lower.
3.80
P/B
Median3y
8.10
Median5y
8.10
-73.95
FCF Yield
Median3y
-11.91
Median5y
-11.91
Competitors Valuation Multiple
The average P/S ratio for BMGL's competitors is 0.00, providing a benchmark for relative valuation. Basel Medical Group Ltd Corp (BMGL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BMGL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BMGL in the past 1 year is driven by Unknown.
Is Basel Medical Group Ltd (BMGL) currently overvalued or undervalued?
Basel Medical Group Ltd(BMGL)is now in theFairzone, suggesting that its currentforward PSratio of 0.00is consideredFairlycompared with the five-year average of0.00.The fair price of Basel Medical Group Ltd(BMGL)is betweentoaccording to relative valuation methord.
What is Basel Medical Group Ltd (BMGL) fair value?
BMGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Basel Medical Group Ltd (BMGL) is between to according to relative valuation methord.
How does BMGL's valuation metrics compare to the industry average?
The average P/S ratio for BMGL's competitors is 0.00, providing a benchmark for relative valuation. Basel Medical Group Ltd Corp (BMGL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Basel Medical Group Ltd (BMGL) as of Dec 17 2025?
As of Dec 17 2025, Basel Medical Group Ltd (BMGL) has a P/B ratio of 4.24. This indicates that the market values BMGL at 4.24 times its book value.
What is the current FCF Yield for Basel Medical Group Ltd (BMGL) as of Dec 17 2025?
As of Dec 17 2025, Basel Medical Group Ltd (BMGL) has a FCF Yield of 0.00%. This means that for every dollar of Basel Medical Group Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for Basel Medical Group Ltd (BMGL) as of Dec 17 2025?
As of Dec 17 2025, Basel Medical Group Ltd (BMGL) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Basel Medical Group Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Basel Medical Group Ltd (BMGL) as of Dec 17 2025?
As of Dec 17 2025, Basel Medical Group Ltd (BMGL) has a Forward P/S ratio of 0.00. This means the market is valuing BMGL at $0.00 for every dollar of expected revenue over the next 12 months.
